484 related articles for article (PubMed ID: 29247540)
21. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and Safety of Rituximab in Systemic Lupus Erythematosus: A Case Series Describing the Experience of 2 Centers.
Gómez VJ; Carrión-Barberá I; Salman Monte TC; Acosta A; Torrente-Segarra V; Monfort J
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 2):391-395. PubMed ID: 30522941
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux.
Deshayes S; Khellaf M; Zarour A; Layese R; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Cliquennois M; Ebbo M; Le Guenno G; Salles G; Bonmati C; Teillet F; Galicier L; Lambotte O; Hot A; Lefrère F; Mahévas M; Canoui-Poitrine F; Michel M; Godeau B
Am J Hematol; 2019 Dec; 94(12):1314-1324. PubMed ID: 31489694
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients.
Gobert D; Bussel JB; Cunningham-Rundles C; Galicier L; Dechartres A; Berezne A; Bonnotte B; DeRevel T; Auzary C; Jaussaud R; Larroche C; LeQuellec A; Ruivard M; Seve P; Smail A; Viallard JF; Godeau B; Hermine O; Michel M
Br J Haematol; 2011 Nov; 155(4):498-508. PubMed ID: 21981575
[TBL] [Abstract][Full Text] [Related]
25. Rituximab Unveils Hypogammaglobulinemia and Immunodeficiency in Children with Autoimmune Cytopenia.
Ottaviano G; Marinoni M; Graziani S; Sibson K; Barzaghi F; Bertolini P; Chini L; Corti P; Cancrini C; D'Alba I; Gabelli M; Gallo V; Giancotta C; Giordano P; Lassandro G; Martire B; Angarano R; Mastrodicasa E; Bava C; Miano M; Naviglio S; Verzegnassi F; Saracco P; Trizzino A; Biondi A; Pignata C; Moschese V
J Allergy Clin Immunol Pract; 2020 Jan; 8(1):273-282. PubMed ID: 31377437
[TBL] [Abstract][Full Text] [Related]
26. Combined pure red cell aplasia and autoimmune hemolytic anemia in systemic lupus erythematosus with anti-erythropoietin autoantibodies.
Hara A; Wada T; Kitajima S; Toyama T; Okumura T; Kitagawa K; Iwata Y; Sakai N; Furuichi K; Higuchi M; Kaneko S
Am J Hematol; 2008 Sep; 83(9):750-2. PubMed ID: 18626921
[TBL] [Abstract][Full Text] [Related]
27. New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination.
Hidaka D; Ogasawara R; Sugimura S; Fujii F; Kojima K; Nagai J; Ebata K; Okada K; Kobayashi N; Ogasawara M; Imamura M; Ota S
Int J Hematol; 2022 Mar; 115(3):424-427. PubMed ID: 34687421
[TBL] [Abstract][Full Text] [Related]
28. Expanded utilization of rituximab in paediatric cardiac transplant patients.
Kiskaddon AL; Landmesser K; Carapellucci J; Wisotzkey B; Asante-Korang A
J Clin Pharm Ther; 2021 Jun; 46(3):762-766. PubMed ID: 33393702
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.
Gokcebay DG; Tavil B; Fettah A; Yarali N; Azik FM; Tunc B
Clin Appl Thromb Hemost; 2013; 19(6):663-7. PubMed ID: 22815318
[TBL] [Abstract][Full Text] [Related]
30. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.
Provan D; Butler T; Evangelista ML; Amadori S; Newland AC; Stasi R
Haematologica; 2007 Dec; 92(12):1695-8. PubMed ID: 18055995
[TBL] [Abstract][Full Text] [Related]
31. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide.
Gupta RK; Ezeonyeji AN; Thomas AS; Scully MA; Ehrenstein MR; Isenberg DA
Lupus; 2011 Dec; 20(14):1547-50. PubMed ID: 21993386
[TBL] [Abstract][Full Text] [Related]
32. Rituximab as maintenance therapy following remission induction in relapsing or refractory systemic lupus erythematosus.
Chen X; Shi X; Xue H; Lv H; Yu L; Wu X; Wang Q; Wu H; Han F; Xue J
Rheumatology (Oxford); 2023 Mar; 62(3):1145-1152. PubMed ID: 35976105
[TBL] [Abstract][Full Text] [Related]
33. Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients.
Cassia MA; Alberici F; Jones RB; Smith RM; Casazza G; Urban ML; Emmi G; Moroni G; Sinico RA; Messa P; Hall F; Vaglio A; Gallieni M; Jayne DR
Arthritis Rheumatol; 2019 Oct; 71(10):1670-1680. PubMed ID: 31102498
[TBL] [Abstract][Full Text] [Related]
34. Significance of autoimmune haemolytic anaemia and immune thrombocytopenia (Evans' syndrome) in systemic lupus erythematosus.
Pasangna J; Lim CB; Duraisamy G; Lajin I
Malays J Pathol; 1994 Jun; 16(1):79-82. PubMed ID: 16329581
[TBL] [Abstract][Full Text] [Related]
35. Treatment and outcomes of immune cytopenias following solid organ transplant in children.
Schoettler M; Elisofon SA; Kim HB; Blume ED; Rodig N; Boyer D; Neufeld EJ; Grace RF
Pediatr Blood Cancer; 2015 Feb; 62(2):214-218. PubMed ID: 25308853
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment with belimumab for immune thrombocytopenia associated with systemic lupus erythematosus: A report of two cases.
Nakayama K; Tamimoto Y; Nakayama T
Mod Rheumatol Case Rep; 2023 Dec; 8(1):69-73. PubMed ID: 37718578
[TBL] [Abstract][Full Text] [Related]
37. Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new.
Newman K; Owlia MB; El-Hemaidi I; Akhtari M
Autoimmun Rev; 2013 May; 12(7):784-91. PubMed ID: 23462431
[TBL] [Abstract][Full Text] [Related]
38. [Rituximab for treatment of patients with systemic autoimmune diseases].
García Hernández FJ; Ocaña Medina C; González León R; Garrido Rasco R; Colorado Bonilla R; Castillo Palma MJ; Sánchez Román J
Med Clin (Barc); 2007 Mar; 128(12):458-62. PubMed ID: 17408540
[TBL] [Abstract][Full Text] [Related]
39. Thrombotic thrombocytopenic purpura that developed 3 years after systemic lupus erythematosus had remitted with rituximab therapy.
Tsuda R; Kido T; Okada I; Kobiyama A; Kawataka M; Yamazaki M; Asano R; Hounoki H; Shinoda K; Tobe K
Mod Rheumatol Case Rep; 2023 Dec; 8(1):57-62. PubMed ID: 37341710
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
Aitken L; Patel R; D'Rozario J; Choi P
Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
